|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270.10 USD | -3.51% |
|
-6.19% | -11.10% |
| 02/06 | BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says | MT |
| 02/06 | RBC Raises Price Target on BeOne Medicines to $436 From $425, Keeps Outperform Rating | MT |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 534.3Cr | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 823.63Cr | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 1.63TCr | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 288.36Cr | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 856.64Cr | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 85Cr | -31.67% | -18.92% | - | - | 1.57x | |
| 253.02Cr | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 94Cr | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 825.13Cr | 2.78% | 16.66% | 10.62% | 6.02% | 1.8x | |
| 401.54Cr | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 51Cr | -13.19% | -41.67% | -31.26% | -21.6% | -0.14x | |
| 127.18Cr | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 121.96Cr | 6.02% | 31.45% | 15.37% | 11.65% | 0.43x | |
| 54.01L | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 209Cr | 20.33% | 29.46% | 17.5% | 10.73% | 0.74x | |
| 147.59Cr | 16.37% | 17.21% | 14.72% | 10.64% | -2.06x | |
| 2.23Cr | -1,027.25% | -1,135.61% | -53.42% | - | 1.65x | |
| Average | 379.53Cr | -489.35% | -374.62% | -6.07% | 4.52% | -2.98x | |
| Weighted average by Cap. | 563.86Cr | -255.88% | -190.57% | 5.12% | 5.78% | -1.39x |
- Stock Market
- Equities
- ONC Stock
- Sector BeOne Medicines AG
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition